GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Quick Ratio

BFRI (Biofrontera) Quick Ratio : 0.94 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biofrontera's quick ratio for the quarter that ended in Sep. 2024 was 0.94.

Biofrontera has a quick ratio of 0.94. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Biofrontera's Quick Ratio or its related term are showing as below:

BFRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.42   Med: 1.48   Max: 3.05
Current: 0.94

During the past 5 years, Biofrontera's highest Quick Ratio was 3.05. The lowest was 0.42. And the median was 1.48.

BFRI's Quick Ratio is ranked worse than
66.7% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 1.395 vs BFRI: 0.94

Biofrontera Quick Ratio Historical Data

The historical data trend for Biofrontera's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Quick Ratio Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
1.11 2.82 3.03 1.72 0.67

Biofrontera Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.67 0.94 1.46 0.94

Competitive Comparison of Biofrontera's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera's Quick Ratio falls into.



Biofrontera Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Biofrontera's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(23.075-10.908)/18.088
=0.67

Biofrontera's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(16.931-6.526)/11.032
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera  (NAS:BFRI) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Biofrontera Quick Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera Business Description

Traded in Other Exchanges
N/A
Address
120 Presidential Way, Suite 330, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Executives
Heikki Lanckriet director C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler officer: Chief Financial Officer 84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber director 119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii director 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman director 5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge director 21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera 10 percent owner HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates officer: Controller C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco director, officer: Chief Financial Officer/COO C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert director, officer: Chief Executive Officer C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801